Plasma Resilience: Europe's Lifeline
Medicines made from human plasma are essential for treating various conditions, including rare inherited disorders and immunodeficiencies.
Human plasma, a protein-rich liquid making up 55% of our blood, is crucial for developing these therapies.
Europe's plasma supply chain is vulnerable, relying on donations from over 12 million people annually, governed by EU and international safety standards.
- International Quality Plasma Program (IQPP)
- Plasma Protein Therapeutics Association (PPTA) oversight
Nearly 40% of plasma used in Europe is imported from the United States, highlighting the need to strengthen the plasma supply chain.
Europe's supply chain of this valuable resource is extremely vulnerable.
Author's summary: Europe relies heavily on human plasma donations.